Stockscreener 앱 받기
6.78%
Altimmune Inc 주식(ALT)의 최신 뉴스
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? - Zacks Investment Research
CFO surrenders 4,379 shares in Altimmune (ALT) solely to cover stock-vesting taxes. - Stock Titan
Rights to 36,234 shares accompany options with a $2.76 exercise price awarded by Altimmune (ALT). - Stock Titan
Altimmune (NasdaqGM:ALT) Stock Forecast & Analyst Predictions - simplywall.st
Altimmune (ALT) exec gains stock as 24,000 RSUs vest - Stock Titan
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? - Yahoo Finance
Altimmune at Wells Fargo healthcare conference: pemvidutide push By Investing.com - Investing.com Canada
Altimmune at Wells Fargo healthcare conference: pemvidutide push By Investing.com - Investing.com UK
Altimmune’s (ALT) Three Liver Trials Move Forward At Once - Yahoo Finance
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - marketscreener.com
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Altimmune (NASDAQ:ALT) Trading Up 9.2%Should You Buy? - MarketBeat
Altimmune Inc (ALT) News, Articles, Events & Latest Updates - Stocktwits
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? - Yahoo Finance
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus - Yahoo Finance
HC Wainwright Estimates Altimmune's Q3 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% - Stocktwits
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune (ALT) Rises 2.08% to $2.94 as Shares Hold Above Key SupportActive ETF Flow - Vinanet
Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M - TradingKey
ALT|Altimmune Inc|Price:3.110|Chg%:+0.160 - TradingKey
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares - GuruFocus
Altimmune CEO Jerome Benedict Durso Buys 15,000 Shares at $2.95 Each - Kalkine Media
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each - Stock Titan
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - The Globe and Mail
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - TradingView
Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution? - kalkinemedia.com
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT - MarketBeat
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - Yahoo Finance
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Yahoo Finance Australia
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Altimmune Reports Q2 2026 Financial Results and SEC Filing Highlighting Increased Assets and Equity Raise - kalkinemedia.com
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary - TradingView
Altimmune (ALT) grows cash reserves above $518M while advancing Phase 3 MASH trial - Stock Titan
Altimmune (ALT) Advances Clinical Trials Amidst High Price-to-Sa - GuruFocus
Altimmune Releases Q2 2026 Financial Results - AlphaStreet
William Blair Maintains Altimmune(ALT.US) With Hold Rating - Moomoo
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Altimmune Q2 EPS $(0.12) beats $(0.15) estimate - scanx.trade
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise - Investing.com Australia
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise - Investing.com Canada
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise - Investing.com Nigeria
4.22%
자본화:
|
볼륨(24시간):